CORRECTION

Open Access



Correction to: Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran

Manoochehr Karami^{1,2*}, Pegah Ameri², Jalal Bathaei³, Zeinab Berangi², Tahereh Pashaei⁴, Ali Zahiri³, Seved Mohsen Zahraei⁵, Hussein Erfani³ and Koen Ponnet^{6,7}

Erratum

After publication of the original article [1], the authors noticed that the percentages in Table 2 were incorrect.

The correct version of Table 2 is published in this erratum.

Author details

¹Social Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. ²Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran. ³Deputy for Health, Hamadan University of Medical Sciences, Hamadan, Iran. ⁴Social Determinants of Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran. ⁵Center for Communicable Diseases Control, Ministry of Health, Tehran, Iran. ⁶Department of Communication Studies, Ghent University, Ghent, Belgium. ⁷Faculty of Social Sciences, University of Antwerp, Antwerp, Belgium.

Received: 20 September 2017 Accepted: 21 September 2017 Published online: 05 October 2017

Reference

Karami M, et al. Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran. BMC Immunol. 2017;18:42. doi:10.1186/s12865-017-0226-8.

* Correspondence: ma.karami@umsha.ac.ir

¹Social Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, Iran

²Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran



© The Author(s), 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

| Adverse events | Incidence (per 100 children) Vaccine dose | | | <i>P</i> -value (1 st and 2 nd dose | <i>P</i> -value (2 nd and 3 rd dose |
|------------------------------|---|---|---|--|--|
| | 1 st dose (2 months) N = 373 | 2 nd dose (4 months) N = 372 | 3 rd dose (6 months) N = 374 | comparison) | comparison) |
| Swelling | 79(21.2) | 50(13.4) | 48(12.8) | 0.003 | 0.068 |
| Redness | 50(13.4) | 30(8.1) | 43(11.5) | 0.026 | 0.679 |
| Pain | 190(50.9) | 143(38.4) | 62(16.6) | 0.001 | 0.162 |
| Mild fever | 45(12.1) | 33(8.9) | 63(16.8) | 0.068 | <0.001 |
| High fever | 1(0.3) | 0(0) | 0(0) | 0.388 | NA |
| Drowsiness | 83(22.3) | 72(19.4) | 70(18.7) | 0.310 | 0.725 |
| Anorexia | 65(17.4) | 51(13.7) | 52(13.9) | 0.126 | 1 |
| Restlessness | 35(9.4) | 115(30.9) | 119(31.8) | <0.001 | 0.766 |
| Vomiting | 16(4.3) | 19(5.1) | 17(4.5) | 0.510 | 0.510 |
| Long-term crying | 24(6.4) | 16(4.3) | 22(5.9) | 0.210 | 0.510 |
| Encephalopathy | 0(0) | 0(0) | 0(0) | NA | NA |
| Convulsion | 0(0) | 0(0) | 0(0) | NA | NA |
| History of convulsion | 0(0) | 1(0.3) | 2(0.5) | 0.387 | 0.488 |
| Family history of convulsion | 0(0) | 14(3.8) | 6(1.6) | <0.001 | 0.074 |

Table 2 Comparison of the cumulative incidence rates of complications in the first, second and third doses of the vaccination in children

NA not applicable